Table 1 Reported cases of synchronous bilateral ovarian cancer with different histopathology in each ovary
First author (year) | Patient age | Type of histopathology of right ovarian cancer | Type of histopathology of left ovarian cancer | Presence of endometriosis in the tumors | Immunohistochemical study | Staging of ovarian cancer* | Types of surgery | Types of adjuvant chemotherapy | Prognosis |
|---|---|---|---|---|---|---|---|---|---|
Song (2011) [4] | 58 | Malignant mixed Müllerian tumor (MMMT) | Serous papillary adenocarcinoma | None in both tumors | Rt: CKa + , vimentin+, S-100+, actin−, desmin−, CD34− Lt: NA | IIIB | TAHj + BSOk + PLAl + PANm + OMEn | TCo for 5 cycles | Recurrence and DOD 7 months after the primary treatment |
Bernardez Zapata (2012) [5] | 49 | Endometrioid carcinoma (G2) | Clear cell carcinoma | Yes, in the right ovarian tumor | Rt: WTi-1+, ERf+, PRh+ Lt: CK7b+, p53+, | IB | TAH + BSO + PLA + OME | NA | NAr |
Nayal (2014) [7] | 38 | High-grade serous papillary adenocarcinoma | Clear cell carcinoma | None in both tumors | NA | IIB | TAH + BSO + OME | TC for 6 cycles | NEDq at 2 years after the treatment |
Preeti (2014) [8] | 60 | High-grade serous carcinoma | Clear cell carcinoma | None in both tumors | Rt: CK7+, CEA+, CD15+, WT-1+ Lt: CK7+, WT-1, ER+, p53+, CK20c-, CEAd-, CD15- | IB | TAH + BSO + OME | Chemotherapy with unknown details | NED at 4 months after the surgery |
Khandeparkar (2014) [6] | 65 | Clear cell carcinoma | Endometrioid carcinoma | Yes, in the left ovarian tumor | Rt: p53+, ER+, WT-1-, Lt: ER+, PR+, p53+, EMAe+ | IB | TAH + BSO + OME + appendectomy + peritoneal biopsy | NA | NA |
Gunakan (2018) [9] | 38 | Malignant mixed Müllerian tumor | Serous carcinoma (G3) | None in both tumors | NA | IIIA1 | TAH + BSO + PLA | TC 6 cycles | Recurrence and DODs after 25 months after the initial diagnosis |
Zhao (2108) [10] | 51 | Endometrioid carcinoma | Clear cell carcinoma | Yes, in the left ovarian tumor | Rt: NA Lt: CD15+, CK7+, CK20−, Napsin-A+, p53 + ER + , PR + | IC2 | RSO (prior surgery) and TAH + LSO + PLA + PAN + OME + appendectomy | TC for 5 cycles | NED at 1 year after the treatment |
Sao (2020) [11] | 60 | Endometrioid carcinoma (G1) | Clear cell carcinoma | Yes, in both tumors | Rt: ER + , Napsin-A- Lt HNFg-1β + , Napsin-A + , ER- | IIA | TAH + BSO + PLA + PAN + OME + appendectomy | TC | NA |
Fujimori (present case) | 47 | Endometrioid carcinoma (G2) | High-grade serous carcinoma | None in both tumors | Rt: ER + , PR + , WT-1-, p53-, Napsin-A- Lt: ER + , WT-1 + , PR-, p53- | IIB | TAH + BSO + OME + peritoneal biopsy | TC/DCp for 6 cycles | NED at 1 year after the surgery |